Phage Display Antibody-Based Proteomic Device Using Resonance-Enhanced Detection

Stich, Norbert; Gandhum, A; Matyushin,; Raats, Jos; Mayer, Christian; Y, Alguel; Schalkhammer, Thomas G. M.

doi:10.1166/jnn.2002.111

Cited by 26 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The control of the nanoscale optical properties of silver nanostructures has also led to nanophotonic devices ranging from nanosensors 8 to waveguides, 9 as well as in a wide variety of applications in biotechnology. [10][11][12][13][14] Several recent publications have also reported luminescence from these silver nanoparticles, in particular silver oxide particles, with envisaged applications in optical storage. 15 Recent microscopy studies of nanoscale silver oxide reveals strong photoactivated emission for excitation wavelengths shorter than 520 nm, with multicolor blinking, even from single nanoparticles.…”

Section: Introductionmentioning

confidence: 99%

Luminescent Blinking from Silver Nanostructures.

Geddes¹,

Parfenov²,

Gryczyński³

et al. 2003

ChemInform

View full text Add to dashboard Cite

Silver nanostructures deposited on glass showed luminescent blinking when excited at a high 442 nm irradiance. The irradiance required to photoactivate the silver, was dependent on the nature of the silver nanostructures. Silver fractal-like structures were found to be highly emissive, requiring only ≈30 W/cm 2 for photoactivation as compared to silver island films and spin-coated silver colloids, which required a significantly higher irradiance, > 100 W/cm 2 , to observe similar luminescent emission. In contrast to our recent findings for gold colloids, foci with different color blinking were also observed, with an increase in luminescence intensity as a function of time. We place these findings in context with recent work from our laboratory which employs these silver nanostructures for applications in metal-enhanced fluorescence, a relatively new phenomenon in fluorescence, whereby metallic particles, colloids, and fractal-like structures can modify the intrinsic radiative decay rate of close proximity fluorescent species. These effects are a consequence of localized changes in photonic mode density around the fluorophores, and we can now report are typically observed at significantly lower illumination intensities as compared to those required to photoactivate silver. Subsequently, our findings strongly suggest that the enhanced fluorescence emission of fluorophores positioned in close proximity to metallic silver structures is not due to either intrinsic silver blinking, or indeed the silver luminescence pumping the fluorophore. Further, the intrinsic luminescence properties of silver reported here, suggest a new class of luminescence probes and labels.

show abstract

Section: Introductionmentioning

confidence: 99%

Luminescent Blinking from Silver Nanostructures.

Geddes¹,

Parfenov²,

Gryczyński³

et al. 2003

ChemInform

View full text Add to dashboard Cite

show abstract

“…In Table 1 we list a few examples of engineered antibody (e.g. scFv, Vh, Fab)-based immunoassays for detection of viruses, cytochrome P450s (catalytic cellular enzymes that oxidize organic substances), IgG by use of a QCM [23, 24], small molecules, toxins, prostate-specific antigen (PSA), and bacteria by SPR [22], and Her2 by use of a piezoelectric microcantilever [25] and other biosensors [26–28]. …”

Section: Scfv Immunosensors and Immunoassaysmentioning

confidence: 99%

Recombinant antibodies and their use in biosensors

2011

View full text Add to dashboard Cite

Inexpensive, noninvasive immunoassays can be used to quickly detect disease in humans. Immunoassay sensitivity and specificity are decidedly dependent upon high-affinity, antigen-specific antibodies. Antibodies are produced biologically. As such, antibody quality and suitability for use in immunoassays cannot be readily determined or controlled by human intervention. However, the process through which high-quality antibodies can be obtained has been shortened and streamlined by use of genetic engineering and recombinant antibody techniques. Antibodies that traditionally take several months or more to produce when animals are used can now be developed in a few weeks as recombinant antibodies produced in bacteria, yeast, or other cell types. Typically most immunoassays use two or more antibodies or antibody fragments to detect antigens that are indicators of disease. However, a label-free biosensor, for example, a quartz-crystal microbalance (QCM) needs one antibody only. As such, the cost and time needed to design and develop an immunoassay can be substantially reduced if recombinant antibodies and biosensors are used rather than traditional antibody and assay (e.g. enzyme-linked immunosorbant assay, ELISA) methods. Unlike traditional antibodies, recombinant antibodies can be genetically engineered to self-assemble on biosensor surfaces, at high density, and correctly oriented to enhance antigen-binding activity and to increase assay sensitivity, specificity, and stability. Additionally, biosensor surface chemistry and physical and electronic properties can be modified to further increase immunoassay performance above and beyond that obtained by use of traditional methods. This review describes some of the techniques investigators have used to develop highly specific and sensitive, recombinant antibody-based biosensors for detection of antigens in simple or complex biological samples.

show abstract

“…For sandwich arrays, monoclonal/polyclonal pairs are more readily available than matched monoclonal antibody pairs targeting different epitopes of a given protein. In vitro selection of antibodies by phage-ribosome or mRNA display technologies and engineered binding molecules have increasingly important roles in generating ligands with specific affinity for analytes, for which antibodies are unavailable (17 ). A novel strategy to produce specific antibodies has been validated, optimizing the design of protein subfragments of a selected size with a minimal sequence similarity to other proteins.…”

Section: Technical Issues Using Planar Antibody Arrays Reagentsmentioning

confidence: 99%

Antibody Arrays: Technical Considerations and Clinical Applications in Cancer

Sänchez‐Carbayo¹

2006

Clinical Chemistry

120

View full text Add to dashboard Cite

Antibody arrays represent one of the high-throughput techniques that are able to detect multiple proteins simultaneously. One of the main advantages of this technology over other proteomic approaches is that the identities of the measured proteins are known or can be readily characterized, allowing a biological interpretation of the results. Features such as lower sample volume and antibody concentration requirements, higher format versatility, and reproducibility support the increasing use of antibody arrays in cancer research. Clinical applications include disease marker discovery for diagnosis, prognosis, and drug response, characterization of signaling and protein pathways, and modifications associated with disease development and progression. This report presents an overview of technical issues of the main antibody array formats and various applications in cancer research. Antibody arrays are high-throughput tools that improve the functional characterization of molecular bases for disease. Furthermore, identification and validation of protein expression patterns, characteristic of cancer progression, and tumor subtypes may intervene and improve tailored therapies in the clinical management of cancer patients.

show abstract

Phage Display Antibody-Based Proteomic Device Using Resonance-Enhanced Detection

Cited by 26 publications

References 0 publications

Luminescent Blinking from Silver Nanostructures.

Luminescent Blinking from Silver Nanostructures.

Recombinant antibodies and their use in biosensors

Antibody Arrays: Technical Considerations and Clinical Applications in Cancer

Contact Info

Product

Resources

About